ZYDUSLIFE

June 2 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• RECEIVES TENTATIVE APPROVAL FROM USFDA FOR RIFAXIMIN TABLETS

Source text: ID:nBSEbXtvH4

Further company coverage: ZYDU.NS

(([email protected];;))

May 20 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES LTD - NITIN PAREKH TO SUPERANNUATE AS CFO EFFECTIVE AUGUST 31, 2025

• ZYDUS LIFESCIENCES LTD - TUSHAR SHROFF APPOINTED AS CFO EFFECTIVE SEPTEMBER 1, 2025

Source text: ID:nBSEccXdGV

Further company coverage: ZYDU.NS

(([email protected];;))

Adds analyst comment in paragraph 6-7, updates shares

May 12 (Reuters) - Indian pharma stocks .NIPHARM fell 1.6% on Monday, bucking broader market gains, after U.S. President Trump said he would cut drug prices by 30%–80% to match other wealthy nations.

Trump said he would sign an executive order on Monday to pursue "most favored nation" pricing.

The U.S. currently pays nearly three times more for many prescription drugs, though Trump offered no implementation details. Several Indian drugmakers earn a significant share of their revenue from North America by selling low-cost generic versions of newer drugs.

Thirteen of 20 stocks on the pharma sub-index fell, led by Sun Pharma’s 4.6% drop, even as the Nifty 50 .NSEI gained 2.5%; Zydus Life ZYDU.NS and Cipla CIPL.NS also declined 0.7% each.

Divi's Laboratories DIVI.NS and Lupin LUPN.NS fell 2% each, while Biocon BION.NS lost nearly 3%.

"A price cut of prescription drugs by 50% or more would hurt the U.S. formulations market, more on the branded size due to immediate potential impact, while over the medium term it will also impact generics as it reduces the potential market size of new drugs," said Shrikant Akolkar, an analyst at Nuvama Institutional Equities.

"Indian branded players like Sun Pharma, Biocon and Zydus Life may see an impact upon strict implementation," Akolkar said.

The U.S. accounts for nearly a third of India's pharma exports, which rose 16% to about $9 billion last fiscal year, according to government-backed trade body Pharmexcil.

(Reporting by Kashish Tandon in Bengaluru; Editing by Nivedita Bhattacharjee and Mrigank Dhaniwala)

(([email protected]; 8800437922;))

April 25 (Reuters) - Amplitude Surgical SA AMPLI.PA/ZYDUS LIFESCIENCES:

• ZYDUS LIFESCIENCES LIMITED SIGNS PURCHASE AGREEMENT WITH PAI PARTNERS AND OTHER SHAREHOLDERS TO ACQUIRE A MAJORITY STAKE IN AMPLITUDE SURGICAL SA

• Zydus has signed the share purchase agreement to acquire 75.4% of the share capital of Amplitude1 at a price of €6.25 per Amplitude share from PAI Partners, Olivier Jallabert and other managers of Amplitude

• SUBJECT TO FULFILMENT OF CLOSING CONDITIONS, ZYDUS WILL ACQUIRE 85.6% OF SHARE CAPITAL OF AMPLITUDE.

Source text: ID:nBw8Q0mba

Further company coverage: AMPLI.PA

(Reporting by Sudip Kar-Gupta)

(([email protected];))

April 17 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS MEDTECH TO MARKET TAVI TECHNOLOGY IN INDIA, EUROPE

• ZYDUS MEDTECH PARTNERS WITH BRAILE BIOMEDICA TO COMMERCIALIZE TAVI

Source text: ID:nBSE2bMbGC

Further company coverage: ZYDU.NS

(([email protected];;))

April 16 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• US COURT RULES AGAINST ZYDUS IN PATENT LITIGATION

• EVALUATING IMPACT AND LEGAL REMEDIES OF COURT ORDER

Source text: ID:nBSEcdr2FK

Further company coverage: ZYDU.NS

(([email protected];;))

April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.

U.S. accounts for a third of India's overall pharma exports.

Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.

On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.

Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.

Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.

The pharma index has fallen 14.4% this year.

(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)

(([email protected];))

March 28 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES - EXTEND CLOSE OF DEAL WITH STERLING BIOTECH TO SEPTEMBER 30, 2025

Source text: [ID:]

Further company coverage: ZYDU.NS

(([email protected];))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

March 12 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES - RECEIVES FINAL APPROVAL FROM USFDA FOR METHENAMINE HIPPURATE TABLETS USP, 1 GRAM

Source text: [ID:]

Further company coverage: ZYDU.NS

(([email protected];;))

March 11 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES LTD - TO ACQUIRE 85.6% STAKE IN AMPLITUDE SURGICAL

• ZYDUS LIFESCIENCES LTD - ACQUISITION PRICE EURO 6.25 PER SHARE, TOTAL VALUE EURO 256.8 MILLION

• ZYDUS LIFESCIENCES LTD - PLANS TO DELIST AMPLITUDE SURGICAL AFTER ACQUISITION

• ZYDUS LIFESCIENCES LTD - TOTAL CONSIDERATION FOR 100% EQUITY SHARE CAPITAL EURO 300 MILLION

Source text: ID:nBSE2njy48

Further company coverage: ZYDU.NS

(([email protected];;))

March 5 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES - LAUNCHES ANVIMO, FOR TRANSPLANT PATIENTS FOR INDIA

Further company coverage: ZYDU.NS

(([email protected];))

March 4 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• TO DEVELOP COMBINATION VACCINE TO PROTECT AGAINST SHIGELLOSIS, TYPHOID FOR INFANTS, CHILDREN

• PROJECT SUPPORTED BY GATES FOUNDATION TO START IN MARCH 2025

Further company coverage: ZYDU.NS

(([email protected];;))

March 3 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES - PENALTY OF 4.27 MILLION RUPEES IMPOSED ON ZYDUS HEALTHCARE

Source text: ID:nNSEc4g5PY

Further company coverage: ZYDU.NS

(([email protected];))

Feb 26 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES - READY TO LAUNCH PROTECTION AGAINST NEW INFLUENZA STRAIN

• ZYDUS LIFESCIENCES - QUADRIVALENT VACCINE CLEARED BY CENTRAL DRUG LABORATORY

Source text: ID:nNSE893MkZ

Further company coverage: ZYDU.NS

(([email protected];))

By Rishika Sadam

HYDERABAD, India, Feb 21 (Reuters) - Indian pharmaceutical companies will be able to retain their dominant market share in the U.S. in selling generic drugs even if President Donald Trump imposes high tariffs because they are "highly competitive", a government-backed trade body said.

The U.S. accounts for nearly a third of India's pharmaceutical exports, mainly cheaper versions of popular drugs, with sales jumping 16% to about $9 billion last fiscal year.

Trump has said he could impose tariffs of 25% or more on pharmaceutical imports and an announcement could be made by next month. India's drug industry has said it hopes bilateral talks will earn them an exception, though Trump has ruled out any such concession so far.

The Pharmaceuticals Export Promotion Council of India (Pharmexcil), set up by the trade ministry, said it believed that the Trump warning was mostly directed at costly imports of patented and other such products from other countries.

"India pharma will not selectively be imposed high duties and its exports are highly competitive, so it can still compete in the newer environment (with import duties if at all imposed) without losing its share," Pharmexcil Director General Raja Bhanu told Reuters.

"The government will certainly have discussions about the changing situations and try to bring the best possible solution."

India imposes about 10% tax on pharma imports from the U.S. while paying nearly no tariff for its exports to the country, according to industry experts.

India sells about 65% of all generic drugs in the U.S, according to Citi Research. According to the Indian government, generic drugs are 50% to 90% cheaper than branded ones.

Higher tariffs will further pressure thin margins of up to 15% of core earnings for most Indian generic drugs unless costs are passed onto consumers, analysts said.

"Tariffs (if not passed through) may result in a large part of the Indian generic drug supply to the U.S. turning unviable," Citi Research said in a note.

"Companies may be forced to rationalize portfolios or (make) exits that may result in massive shortages in the U.S. and resultant drug price increases. If Indian players start exiting from the generics, drug shortages in the U.S. may escalate beyond control."

According to research firm IQVIA, overall cheaper generic drugs saved the U.S. healthcare system about $408 billion in 2022.

Sun Pharma SUN.NS, India's largest drugmaker that made 32%of its total revenue through U.S. sales last fiscal year, has already said it will pass on any costs to consumers.

Other big Indian players include Dr Reddy's REDY.NS, Cipla CIPL.NS and Zydus Lifesciences ZYDU.NS.

The tariff uncertainty could dominate discussions at the BioAsia conference in India's Telangana state next week, expected to be attended by executives from pharma giants including Eli Lilly LLY.N, Novo Nordisk NOVOb.CO.

(Reporting by Rishika Sadam in Hyderabad; Kashish Tanon and Bhanvi Satija in Bengaluru; editing by David Evans)

(([email protected];))

** Shares of Indian drugmaker Zydus Lifesciences ZYDU.NS gain 2.2% to 921.7 rupees

** Co says U.S. health regulator closes inspection at API manufacturing plant in Maharashtra with no observations

** Average rating of 28 analysts on ZYDU is "hold" and median PT is 1,050 rupees, ~14% above current price -LSEG data

** ZYDU rose 41% in 2024

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Feb 12 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• AND SYNTHON SIGN EXCLUSIVE AGREEMENT FOR US ONCOLOGY PRODUCT

• SYNTHON TO HANDLE DEVELOPMENT, MANUFACTURING

• ZYDUS TO HANDLE US COMMERCIALIZATION

Source text: ID:nNSE97GfVh

Further company coverage: ZYDU.NS

(([email protected];;))

** Shares of Zydus Lifesciences ZYDU.NS rise 3.4% to 1,009 rupees

** Stock has gained 5% since posting results on Wednesday

** Co posted Q3 profit above analysts' expectations, driven by strong demand for its generic drugs in its key U.S. market

** Product specific opportunities present in US market to benefit co, said analysts at Nomura

** Adds, expect growth in domestic businesses to contribute ~44% of EBITDA in FY27

** Investments in specialty and vaccine likely to contribute materially beyond FY27- Nomura

** Co to deliver high-single-digit Y/Y growth in US sales in FY26- Motilal Oswal

** More than 5.4 mln shares change hands, 4.2x its 30-day avg

** 28 analysts covering the stock on avg have a "hold" rating; median PT is 1,050 rupees - LSEG data

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Jan 22 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS ANNOUNCES USFDA ORPHAN DRUG DESIGNATION TO USNOFLAST

Source text: [ID:]

Further company coverage: ZYDU.NS

(([email protected];;))

** Shares of Zydus Lifesciences ZYDU.NS close ~3% higher at 1,010.50 rupees

** Nomura upgrades stock to 'buy' from 'neutral', raises PT to 1,140 rupees from 1,030 rupees, implying a ~13% upside

** Sales to rise after CVS Health's CVS.N subsidiary CVS Caremark added co's medications to its template formulary nL4N3O30ML

** Formulary is a list of prescription medicines covered by a health insurance plan

** Brokerage raises Zydus Lifesciences' FY26 and FY27 earnings estimates by 6% each; estimates opportunity size for Zydus to be ~$100 mln to $150 mln

** Shares of co have gained ~38% in last 12 months vs 24.3% gain in the Nifty pharma sub index .NIPHARM

($1 = 85.8790 Indian rupees)

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

** Shares of Zydus Lifesciences ZYDU.NS rise about 4% to 999.65 rupees

** Stock second-biggest gainer on the Nifty pharma sub index .NIPHARM, which is up 0.76%

** Co signs an agreement with U.S. based CVS Health's CVS.N subsidiary CVS Caremark to add 3 tablets to CVS Caremark's template formulary

** Formulary indicates a list of prescription medicines covered by a health insurance plan

** Tablets contain active ingredients that improve glycemic control in adults with type 2 diabetes

** ZYDU rated 'hold' on avg, among 11 stocks out of 20 on pharma index with this rating - LSEG

** Stock extends 12-month gain to around 40%, compared to a ~33% jump in pharma sub index in same period

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Dec 19 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• RECEIVES FINAL USFDA APPROVAL FOR LIDOCAINE AND PRILOCAINE CREAM

Source text: ID:nNSE8MVjXc

Further company coverage: ZYDU.NS

(([email protected];))

Dec 16 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES - DISINVESTMENT OF EQUITY STAKE OF MYLAB DISCOVERY SOLUTIONS

• ZYDUS LIFESCIENCES LTD - ZAHL ACQUIRED 6.5% STAKE IN MYLAB FOR 1.06 BILLION RUPEES

• ZYDUS LIFESCIENCES - CONSIDERATION RECEIVED FROM SALE 1.06 BILLION RUPEES

Source text: ID:nBSEgMHdd

Further company coverage: ZYDU.NS

(([email protected];))

Nov 29 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• GOT TOTAL TAX DEMAND ORDER FOR 16.1 MILLION RUPEES

Source text: ID:nBSE6MyPYr

Further company coverage: ZYDU.NS

(([email protected];;))

Nov 12 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES Q2 CONSOL NET PROFIT 9.11 BILLION RUPEES; IBES PROFIT EST. 9.13 BILLION RUPEES

• ZYDUS LIFESCIENCES Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 52.37 BILLION RUPEES; IBES EST. 51.85 BILLION RUPEES

Source text: [ID:]

Further company coverage: ZYDU.NS

(([email protected];;))

Oct 23 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• ZYDUS LIFESCIENCES - WHO PREQUALIFIES ZYDUS'S TYPHOID VI CONJUGATE VACCINE, ZYVAC TCV

• ZYDUS LIFESCIENCES - ZYVAC TCV ELIGIBLE FOR PURCHASE BY UNITED NATIONS PROCUREMENT AGENCIES

Further company coverage: ZYDU.NS

(([email protected];))

Oct 17 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:

• GETS FINAL APPROVAL FROM USFDA FOR FLUDROCORTISONE ACETATE TABLETS USP, 0.1 MG

Source text for Eikon: ID:nNSE21QP1f

Further company coverage: ZYDU.NS

(([email protected];))